Development
Evaxion Biotech A/S
EVAX
$3.13
$0.5521.32%
NASDAQ
| 09/30/2023 | 06/30/2023 | 12/31/2022 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 45.51% | 27.67% | 56.48% | 34.78% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -5.28% | -9.30% | -15.49% | 2.89% | |
| Operating Income | 5.28% | 9.30% | 15.49% | -2.89% | |
| Income Before Tax | 0.73% | -19.47% | 0.03% | -4.23% | |
| Income Tax Expenses | -10.86% | -27.12% | -113.08% | 58.82% | |
| Earnings from Continuing Operations | 1.08% | -19.19% | 17.90% | -9.33% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | 1.08% | -19.19% | 17.90% | -9.33% | |
| EBIT | 5.28% | 9.30% | 15.49% | -2.89% | |
| EBITDA | 7.94% | 11.11% | 16.20% | -2.65% | |
| EPS Basic | 12.50% | -5.00% | 26.10% | 11.11% | |
| Normalized Basic EPS | 12.19% | -5.25% | 10.04% | 15.26% | |
| EPS Diluted | 12.50% | -5.00% | 26.10% | 11.11% | |
| Normalized Diluted EPS | 12.19% | -5.25% | 10.04% | 15.26% | |
| Average Basic Shares Outstanding | 13.05% | 13.51% | 11.12% | 23.00% | |
| Average Diluted Shares Outstanding | 13.05% | 13.51% | 11.12% | 22.99% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |